Traws Pharma (TRAW) Common Equity (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Common Equity of -$5.3 million for Q1 2026, down 188.52% year-over-year from $6.0 million in Q1 2025, and down 744.36% quarter-over-quarter from -$629000.0 in Q4 2025.
Traws Pharma (TRAW) Common Equity (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Common Equity for 15 consecutive years, with -$5.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 188.52% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$5.3 million (down 188.52% YoY), while the FY2025 annual figure was -$629000.0, up 98.01% from the prior year.
- Common Equity retreated to -$5.3 million in Q1 2026 per TRAW's latest filing, from -$629000.0 in the prior quarter.
- Across five years, Common Equity topped out at $42.3 million in Q1 2022 and bottomed at -$105.5 million in Q2 2024.
- Historically, Common Equity has averaged $5.2 million across 5 years, with a median of $8.3 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity sank 658.37% — and 2025, when it surged 323.56%.
- Traws Pharma's Common Equity stood at $28.3 million in 2022, then slumped by 62.3% to $10.7 million in 2023, then plunged by 396.38% to -$31.6 million in 2024, then soared by 98.01% to -$629000.0 in 2025, then sank by 744.36% to -$5.3 million in 2026.
- Business Quant data shows TRAW's Common Equity at -$5.3 million in Q1 2026, -$629000.0 in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | 1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.31 Mn |
| Dec 31, 2025 | -629,000.00 |
| Sep 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | 8.26 Mn |
| Mar 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | -31.63 Mn |
| Sep 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | -105.52 Mn |
| Mar 31, 2024 | 6.02 Mn |
| Dec 31, 2023 | 10.67 Mn |
| Sep 30, 2023 | 14.52 Mn |
| Jun 30, 2023 | 18.90 Mn |
| Mar 31, 2023 | 22.88 Mn |
| Dec 31, 2022 | 28.31 Mn |
| Sep 30, 2022 | 33.37 Mn |
| Jun 30, 2022 | 38.48 Mn |
| Mar 31, 2022 | 42.29 Mn |
| Dec 31, 2021 | 46.12 Mn |
| Sep 30, 2021 | 49.67 Mn |
| Jun 30, 2021 | 32.99 Mn |